Bacil Pharma
BSE: BACPHAR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bacil Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bacil Pharma Limited is an Indian public limited company historically engaged in the manufacturing and trading of pharmaceutical formulations and bulk drugs. The company has transitioned into a shell entity with minimal active business operations in the healthcare sector.
Business Model
The company currently operates as a shell entity with limited revenue from operations, focusing primarily on administrative maintenance to retain its listed status.
Management Commentary
There is no recent management commentary available regarding the company's strategic direction or operational status.
Growth Outlook
The company lacks a clear growth strategy as it currently functions as a dormant entity with minimal operational activity.
Key Risks
- Regulatory Delisting Risk. The company faces potential delisting by the Bombay Stock Exchange or SEBI due to its dormant operational status and lack of significant business activity.
- Liquidity Risk. As a shell entity with minimal revenue, the company may struggle to meet ongoing administrative and compliance costs.
- Operational Viability. The absence of core pharmaceutical manufacturing or trading activities renders the company's long-term business model unsustainable.
Start your research today
Unlock AI insights, financials, peers and live data on Bacil Pharma and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹1 Cr
TTM · standalone
EPS
₹1.40
TTM · standalone
RETURN ON EQUITY
15.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
18.4%
TTM · standalone
P/E
19.5x
Q1 FY26 · standalone
EV/EBITDA
23.6x
Q1 FY26 · standalone
DEBT TO EQUITY
0.0x
Q2 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bacil PharmaBACPHAR | ₹34 Cr | 19.49 | 23.64 | — | — | 15.3% | 18.4% | -37.3% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q1 FY26
Financials
Bacil Pharma
BSE: BACPHAR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bacil Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bacil Pharma Limited is an Indian public limited company historically engaged in the manufacturing and trading of pharmaceutical formulations and bulk drugs. The company has transitioned into a shell entity with minimal active business operations in the healthcare sector.
Business Model
The company currently operates as a shell entity with limited revenue from operations, focusing primarily on administrative maintenance to retain its listed status.
Management Commentary
There is no recent management commentary available regarding the company's strategic direction or operational status.
Growth Outlook
The company lacks a clear growth strategy as it currently functions as a dormant entity with minimal operational activity.
Key Risks
- Regulatory Delisting Risk. The company faces potential delisting by the Bombay Stock Exchange or SEBI due to its dormant operational status and lack of significant business activity.
- Liquidity Risk. As a shell entity with minimal revenue, the company may struggle to meet ongoing administrative and compliance costs.
- Operational Viability. The absence of core pharmaceutical manufacturing or trading activities renders the company's long-term business model unsustainable.
Start your research today
Unlock AI insights, financials, peers and live data on Bacil Pharma and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹1 Cr
TTM · standalone
EPS
₹1.40
TTM · standalone
RETURN ON EQUITY
15.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
18.4%
TTM · standalone
P/E
19.5x
Q1 FY26 · standalone
EV/EBITDA
23.6x
Q1 FY26 · standalone
DEBT TO EQUITY
0.0x
Q2 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26